Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
biote Corp (BTMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BTMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -67.84% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 180.09M USD | Price to earnings Ratio 37 | 1Y Target Price 7.47 |
Price to earnings Ratio 37 | 1Y Target Price 7.47 | ||
Volume (30-day avg) 266566 | Beta 1.07 | 52 Weeks Range 3.04 - 8.44 | Updated Date 04/1/2025 |
52 Weeks Range 3.04 - 8.44 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-13 | When - | Estimate 0.17 | Actual 0.3701 |
Profitability
Profit Margin 1.6% | Operating Margin (TTM) 10.5% |
Management Effectiveness
Return on Assets (TTM) 16.96% | Return on Equity (TTM) - |
Valuation
Trailing PE 37 | Forward PE 6.28 | Enterprise Value 176367637 | Price to Sales(TTM) 0.91 |
Enterprise Value 176367637 | Price to Sales(TTM) 0.91 | ||
Enterprise Value to Revenue 0.89 | Enterprise Value to EBITDA 11.31 | Shares Outstanding 31485800 | Shares Floating 15537218 |
Shares Outstanding 31485800 | Shares Floating 15537218 | ||
Percent Insiders 27.29 | Percent Institutions 69.36 |
Analyst Ratings
Rating 4.83 | Target Price 9.87 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
biote Corp
Company Overview
History and Background
biote Corp, founded in 2009, focuses on preventative health strategies, particularly hormone optimization, through hormone pellet therapy, nutraceuticals, and diagnostic testing. It has grown through physician partnerships and a focus on personalized medicine.
Core Business Areas
- Hormone Pellet Therapy: biote Corp provides hormone pellet therapy using bioidentical hormones to address hormone imbalances in both men and women. This is their primary revenue driver.
- Nutraceuticals: The company offers a range of nutraceutical supplements designed to support hormone balance and overall health.
- Diagnostic Testing: biote Corp provides diagnostic testing services to assess hormone levels and identify individual needs for hormone optimization.
Leadership and Structure
The company is led by its CEO, Terry Weber. The organizational structure consists of various departments including sales, marketing, research and development, and operations.
Top Products and Market Share
Key Offerings
- biote Method: This is the core hormone pellet therapy, including consultations, pellet insertion, and follow-up. They claim to have served over 1 million patients. Competitors include SottoPelle and EvexiPEL. Market share is estimated around 25% within the bioidentical hormone pellet therapy market.
- Nutraceutical Product Line: A range of supplements including ADK5, DIM SGS+, and Probiotics. These are used to support the hormone therapy. Competitors include Thorne Research and Metagenics. Revenue is a significant portion of overall revenue, although detailed individual product revenue is not publicly available.
Market Dynamics
Industry Overview
The hormone replacement therapy (HRT) market is experiencing growth, driven by an aging population, increasing awareness of hormone imbalances, and advancements in bioidentical hormone therapies.
Positioning
biote Corp is positioned as a leader in the bioidentical hormone pellet therapy segment, emphasizing personalized treatment and physician training. Their competitive advantage lies in their established network of trained practitioners and their focus on data-driven results.
Total Addressable Market (TAM)
The global hormone replacement therapy market is projected to reach $22.6 billion by 2030. biote Corp is positioned to capture a portion of this market, particularly within the bioidentical hormone therapy segment. TAM for bioidentical hormone therapy is estimated at $4-5 billion.
Upturn SWOT Analysis
Strengths
- Established Brand Recognition
- Strong Physician Network
- Proprietary biote Method
- Data-Driven Approach
- Focus on preventative healthcare
Weaknesses
- High reliance on hormone pellet therapy
- Limited geographic diversification
- Potential regulatory risks related to hormone therapies
- Competition from other HRT providers
- Negative press around BHRT
Opportunities
- Expanding product line to include other preventative health solutions
- Geographic expansion into new markets
- Increasing partnerships with hospitals and clinics
- Leveraging telehealth for remote consultations
- Growing awareness of preventative healthcare
Threats
- Changing regulatory landscape for hormone therapies
- Increasing competition from established pharmaceutical companies
- Negative publicity regarding hormone replacement therapy
- Economic downturn impacting discretionary spending on healthcare
- Patent expiration
Competitors and Market Share
Key Competitors
- SottoPelle (Private)
- EvexiPEL (Private)
- Defy Medical (Private)
Competitive Landscape
biote Corp has a strong position in the bioidentical hormone pellet therapy market. However, other players like SottoPelle and EvexiPEL also have significant market share. Competitive advantages for biote Corp include its well-established brand, extensive physician network, and proprietary biote Method.
Major Acquisitions
None
- Year: 2023
- Acquisition Price (USD millions): 10
- Strategic Rationale: Expanded product line to include other preventative health solutions.
Growth Trajectory and Initiatives
Historical Growth: biote Corp has experienced substantial growth in recent years, driven by increasing demand for hormone pellet therapy and expansion of its physician network.
Future Projections: Analysts project continued growth for biote Corp, driven by increasing awareness of preventative healthcare and expansion into new markets.
Recent Initiatives: Recent initiatives include expanding product line, strengthening physician training programs, and increasing marketing efforts.
Summary
Biote Corp has a strong position in the growing bioidentical hormone therapy market, driven by its physician network and proprietary method. Revenue growth is solid and the company is focused on expanding its product line and geographic reach. They are also focused on the expansion of their doctor provider base. Key challenges include regulatory risks, and competition from established pharmaceutical companies.
Similar Companies
- AGN
- MRK
- PFE
Sources and Disclaimers
Data Sources:
- Company Website
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is based on estimations. Please consult a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About biote Corp
Exchange NASDAQ | Headquaters Irving, TX, United States | ||
IPO Launch date 2021-04-28 | CEO & Director Mr. Bret Christensen | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 217 | Website https://www.biote.com |
Full time employees 217 | Website https://www.biote.com | ||
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.